01:45:01 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-07 Kvartalsrapport 2024-Q2
2024-06-06 X-dag ordinarie utdelning BIOBV 0.00 EUR
2024-06-05 Årsstämma
2024-02-14 Bokslutskommuniké 2023
2023-08-09 Kvartalsrapport 2023-Q2
2023-06-15 X-dag ordinarie utdelning BIOBV 0.00 EUR
2023-06-14 Årsstämma
2023-03-22 Bokslutskommuniké 2022
2022-08-10 Kvartalsrapport 2022-Q2
2022-06-16 X-dag ordinarie utdelning BIOBV 0.00 EUR
2022-06-15 Årsstämma
2022-03-09 Extra Bolagsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-08-11 Kvartalsrapport 2021-Q2
2021-04-22 X-dag ordinarie utdelning BIOBV 0.00 EUR
2021-04-21 Årsstämma
2021-02-17 Bokslutskommuniké 2020
2020-08-12 Kvartalsrapport 2020-Q2
2020-04-23 X-dag ordinarie utdelning BIOBV 0.00 EUR
2020-04-22 Årsstämma
2020-02-19 Bokslutskommuniké 2019
2019-08-14 Kvartalsrapport 2019-Q2
2019-04-25 X-dag ordinarie utdelning BIOBV 0.00 EUR
2019-04-24 Årsstämma
2019-02-20 Bokslutskommuniké 2018
2018-08-22 Kvartalsrapport 2018-Q2
2018-08-16 Extra Bolagsstämma 2018
2018-04-26 X-dag ordinarie utdelning BIOBV 0.00 EUR
2018-04-25 Årsstämma
2018-02-28 Bokslutskommuniké 2017
2017-07-27 Kvartalsrapport 2017-Q2
2017-04-27 X-dag ordinarie utdelning BIOBV 0.00 EUR
2017-04-26 Årsstämma
2017-02-02 Bokslutskommuniké 2016
2016-10-20 15-10 2016-Q3
2016-08-10 Kvartalsrapport 2016-Q2
2016-05-12 Kvartalsrapport 2016-Q1
2016-04-26 X-dag ordinarie utdelning BIOBV 0.00 EUR
2016-04-25 Årsstämma
2016-02-25 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2015-05-07 Kvartalsrapport 2015-Q1
2015-04-21 X-dag ordinarie utdelning BIOBV 0.00 EUR
2015-04-20 Årsstämma
2015-02-26 Bokslutskommuniké 2014
2014-10-23 Kvartalsrapport 2014-Q3
2014-08-21 Kvartalsrapport 2014-Q2
2014-05-08 Kvartalsrapport 2014-Q1
2014-04-15 X-dag ordinarie utdelning BIOBV 0.72 EUR
2014-04-14 Årsstämma
2014-02-27 Bokslutskommuniké 2013
2013-10-24 Kvartalsrapport 2013-Q3
2013-08-08 Kvartalsrapport 2013-Q2
2013-04-25 Kvartalsrapport 2013-Q1
2013-04-09 X-dag ordinarie utdelning BIOBV 0.50 EUR
2013-04-08 Årsstämma
2013-02-27 Bokslutskommuniké 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-08-16 Kvartalsrapport 2012-Q2
2012-04-26 Kvartalsrapport 2012-Q1
2012-04-12 X-dag ordinarie utdelning BIOBV 1.00 EUR
2012-04-11 Årsstämma
2012-02-29 Bokslutskommuniké 2011
2011-11-23 Extra Bolagsstämma 2011
2011-10-20 Kvartalsrapport 2011-Q3
2011-08-18 Kvartalsrapport 2011-Q2
2011-04-28 Kvartalsrapport 2011-Q1
2011-04-14 X-dag ordinarie utdelning BIOBV 0.00 EUR
2011-04-13 Årsstämma
2011-03-01 Bokslutskommuniké 2010
2010-04-26 X-dag ordinarie utdelning BIOBV 0.00 EUR
2009-04-21 X-dag ordinarie utdelning BIOBV 0.00 EUR
2008-04-22 X-dag ordinarie utdelning BIOBV 0.00 EUR
2007-04-20 X-dag ordinarie utdelning BIOBV 0.00 EUR
2006-04-21 X-dag ordinarie utdelning BIOBV 0.00 EUR
2005-04-22 X-dag ordinarie utdelning BIOBV 0.00 EUR
2004-04-16 X-dag ordinarie utdelning BIOBV 0.00 EUR
2003-04-10 X-dag ordinarie utdelning BIOBV 0.00 EUR
2002-04-02 X-dag ordinarie utdelning BIOBV 0.00 EUR
2001-03-28 X-dag ordinarie utdelning BIOBV 0.00 EUR
2000-04-07 X-dag ordinarie utdelning BIOBV 0.00 EUR
1999-04-22 X-dag ordinarie utdelning BIOBV 0.00 EUR

Beskrivning

LandFinland
ListaSmall Cap Helsinki
SektorHälsovård
IndustriMedicinteknik
Biohit är verksamt inom medicinteknik. Bolaget utvecklar och tillverkar laboratorieutrustning, förnödenheter samt diagnostiska analyssystem anpassade för forskning, vård och industrilaboratorium. Utöver huvudverksamheten erbjuds teknisk support, underhåll samt utbildningstjänster inom nämnt arbetsområde. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget har sitt huvudkontor i Helsingfors.
2021-08-10 15:15:00

Biohit Oyj stock exchange release 10[th] of August 2021 at 04.15 pm local time (EET)

 

The latest innovation in the unique Biohit GastroPanel product family, GastroPanel quick test, is now CE marked.

GastroPanel quick test is intended for diagnosing Helicobacter pylori infection and atrophic gastritis from patients with dyspeptic symptoms. The test measures pepsinogen I, pepsinogen II, gastrin-17 and antibodies against Helicobacter pylori from a human plasma sample in one test. Test also identifies persons at risk to develop malignant cellular changes in stomach mucosa or who necessitate additional stomach examination or treatment. Test results are available in 20 minutes, allowing fast diagnosis and screening for further examinations.

GastroPanel quick test system comprises of an immunological test and dedicated GP Reader device which interprets the result. The clinical performance of the GastroPanel quick test system is in line with the on market available and previously validated ELISA-based GastroPanel® test.

Samples collected from 500 patients with upper abdominal symptoms at Oulu University Hospital in 2016-2020 were tested with GastroPanel quick test. The results were compared with gastric endoscopies and biopsies performed according to international guidelines. The concordance between the methods was demonstrated to be excellent.

We are excited to launch the GastroPanel quick test system with such excellent performance characteristics and fast turnaround time. We believe that the test system will be well received by end users because the usability of the test system enables first-line diagnosis and screening of dyspeptic patients easier than ever before. We are eager to continue developing the testing system further. Next, we will extend the CE mark of the GastroPanel quick test to include finger-prick blood samples by the end of 2021.

 

ORDERING INFORMATION:

 GastroPanel quick test (product number 602320) and GP reader including embedded interpretation software (product number 602330).

 

Additional information: 
Acting CEO Osmo Suovaniemi, Biohit Oyj
tel. +358 9 773 861

investor.relations@biohit.fi
www.biohithealthcare.com

 

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is "Innovating for Health" - we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com (https://www.globenewswire.com/Tracker?data=ciyb_iZ945H2z3sK3a9i7Zs03Nkj9jr5Brw7kC1tsoUye5PVgko06PC57Z9BVVT2pXUgp6sn-tswLd2MUgQOQc8UNXD2BkNm3L02XzRJ7XfJCPaPUqGS1mpI0NZinK5T)